Donations from Trusts and Foundations are fundamental for our work. As the UK’s leading ovarian cancer charity we work to improve early diagnosis, we fund life-saving research and we provide much-needed support to women with ovarian cancer. We’re the only charity fighting ovarian cancer on all three of these fronts, across all four nations of the UK.
Your support will help us:
- fund ovarian cancer research into vital new treatments and improve survival rates
- provide support and information to women with ovarian cancer and their families
- raise awareness of the signs and symptoms of ovarian cancer to improve early diagnosis and save lives
Get in touch
To find out how you can make a difference to people affected by ovarian cancer, please contact us on 020 7923 5474, or by email.
A special thank you
We are very grateful to the trusts and foundations that give valuable support to our work. Here are just some examples of how they are helping us.
The Louis Baylis Charitable Trust (Maidenhead Advertiser) has supported Target Ovarian Cancer since we launched in 2008. We are very grateful to the Trust for their continued and regular support towards core costs, enabling us to save lives and help women with ovarian cancer live their lives to the full.
The Joseph Levy Foundation has supported our continuing professional development training tools for GPs with a generous grant over the past three years. This work is vital in helping GPs understand the signs and symptoms of ovarian cancer so they can detect it sooner. If diagnosed at the earliest stage, ovarian cancer survival rates increase from just 46 per cent to over 90 per cent.
What our funders say
Sir Christopher Gent, Chairman of GlaxoSmithKline: “Target Ovarian Cancer is an incredibly professional organisation that has achieved a huge amount in just three years. The judging panel were particularly impressed with their impact, which was far beyond what one would expect from the size of the organisation. It has moved ovarian cancer up GPs’ agendas and provided them with the tools to better identify the disease. It is a shining example of what can be achieved in a short space of time and I would like to congratulate them on this.”
Target Ovarian Cancer were overall joint winners of the GSK Impact Awards 2012, run in conjunction with the King’s Fund.